Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma

J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):265-267. doi: 10.18176/jiaci.0637. Epub 2020 Aug 26.

Authors

S N Gonzalez-Diaz¹, R V Villarreal-Gonzalez¹, C E De Lira-Quezada¹, G K Rocha-Silva¹, V M Oyervides-Juarez², O Vidal-Gutierrez²

Affiliations

¹ Regional Center of Allergy and Clinical Immunology, University Hospital "Dr. Jose Eleuterio Gonzalez", Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.
² Oncology Department, University Hospital "Dr. Jose Eleuterio Gonzalez", Faculty of Medicine, Autonomous University of Nuevo León, Monterrey, Mexico.

PMID: 32856592
DOI: 10.18176/jiaci.0637

No abstract available

Keywords: Adenocarcinoma; Anaphylaxis; Atezolizumab; Bevacizumab; Desensitization.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / complications
Adenocarcinoma / drug therapy*
Anaphylaxis / etiology
Anaphylaxis / prevention & control*
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
Bevacizumab / adverse effects
Bevacizumab / therapeutic use*
Desensitization, Immunologic / methods*
Drug Hypersensitivity / complications
Drug Hypersensitivity / therapy*
Drug-Related Side Effects and Adverse Reactions / prevention & control*
Humans
Lung Neoplasms / complications
Lung Neoplasms / drug therapy*
Male
Middle Aged
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Bevacizumab
atezolizumab